“With the support of a syndicate of experienced international investors, we plan to accelerate our ambitious development pipeline,” said Cedric Verberken, CEO of Comfo Therapeutics. “Our plans include potential new treatments for serious and rare endocrine disorders, as well as next-generation obesity medications that could be used in combination with, or as an alternative to, GLP-1R agonists.”
In addition to lead investor Ackermans & van Haaren, new and existing investors participating in the round include BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Partners.
The funding will support a Phase I study of CFTX-1334, an AT2 receptor antagonist, for the treatment of peripheral pain in collaboration with Confo’s partner Lilly, and one of Confo’s proprietary GPCR agonists in lead optimization stage targeting SST receptor 4 (pain), MC1 receptor (fibrosis), or SST receptor 5 (hyperglycemia). In addition, two discovery stage programs will be advanced through IND: a GPR75 antagonist for the treatment of obesity and a PTH receptor 1 agonist for the treatment of hyperparathyroidism. Additionally, a portion of the funding will be dedicated to the discovery of novel class B GPCR modulators for rare endocrine diseases.
As part of the Series B funding round, Dr Vangindertael, investment manager at Ackermans & van Haaren, will join Confo’s board of directors, while Alex Munns, assistant portfolio manager at Driehaus, will be appointed as a board observer.
